On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer.
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education